Video

Dr. Dorff on state of second-line treatment for metastatic urothelial cancer

Author(s):

Urology Times staff
Current Time 0:00
Duration 1:30
Loaded: 0%
Stream Type LIVE
Remaining Time 1:30
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected

    Tanya Dorff, MD, discusses the currently available therapeutic options for patients with metastatic urothelial cancer who have progressed on frontline treatment. Dorff is a medical oncologist, section chief of Genitourinary Disease Program, and associate professor in the Department of Medical Oncology & Therapeutics Research at City of Hope Comprehensive Cancer Center.

    Related Videos
    4 experts in this video
    Non–Muscle Invasive-Bladder Cancer Overview
    Laura Davis, MD, on link between microplastics and bladder cancer
    Laura Davis, MD, on link between microplastics and bladder cancer
    Rebecca A. Campbell, MD, answers a question during a Zoom video interview
    Rebecca A. Campbell, MD, discusses citation rates for men and women in the oncology literature
    Sam Chang, MD, shares updated data on nogapendekin alfa inbakicept in NMIBC
    Sam Chang, MD, shares updated data on nogapendekin alfa inbakicept in NMIBC
    Joshua J. Meeks, MD, PhD, gives an answer during a Zoom video interview
    Expert discusses the NMIBC trials landscape
    John Gore, MD, on bladder preservation in muscle–invasive bladder cancer
    John Gore, MD, on bladder preservation in muscle–invasive bladder cancer
    Félix Guerrero-Ramos, MD, on TAR-200 in papillary disease-only NMIBC
    Félix Guerrero-Ramos, MD, on TAR-200 in papillary disease-only NMIBC
    Joshua J. Meeks, MD, PhD, answers a question during a Zoom video interview
    Joshua J. Meeks, MD, PhD, discusses NIAGARA data for patient undergoing cystectomy
    Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
    Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
    Study data point to gender disparities in oncology research citations
    Study data point to gender disparities in oncology research citations
    Related Content
    FDA Advisory Committee finds evidence for UGN-102 inconclusive, cites uncertainty in benefit-risk
    May 21st 2025

    FDA Advisory Committee finds evidence for UGN-102 inconclusive, cites uncertainty in benefit-risk

    Hannah Clarke
    The committee voted 4-5 in opposition of a favorable benefit-risk profile.
    medical depiction of bladder cancer
    May 31st 2023

    Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

    Urology Times staff
    In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
    Woman talking with a doctor online using digital tablet | Image Credit: © rh2010 - stock.adobe.com
    May 15th 2025

    Telehealth in urologic cancer: Lessons learned from the COVID-19 pandemic

    Tracey L. Krupski, MD Jeunice Owens-Walton, MD
    "The use of telemedicine is heavily dependent on supportive legislature," write Tracey L. Krupski, MD, and Jeunice Owens-Walton, MD.
    Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
    December 7th 2021

    Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app

    Urology Times staff
    “It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
    Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
    May 9th 2025

    Durvalumab plus BCG significantly improves DFS in NMIBC

    Benjamin P. Saylor Hannah Clarke
    The data are to be presented at an upcoming medical conference.
    Physical function and frailty measures offer distinct insights in patients with bladder cancer
    May 7th 2025

    Physical function and frailty measures offer distinct insights in patients with bladder cancer

    Hannah Clarke
    Data showed that physical function and self-reported frailty assessments were poorly correlated.
    © 2025 MJH Life Sciences

    All rights reserved.